Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Clinical trial NCT01126749 · TERMINATED
Trial details
- NCT number
- NCT01126749
- Sponsor
- Eisai Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-04-16
- Primary completion
- 2015-05-08
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.